Dr. Reddy's Delays Semaglutide Supplies Following API-Related Quality Issue
Dr. Reddy's Laboratories announces a temporary delay in commercial supplies of semaglutide after identifying an API-related quality issue affecting certain batches. The company is investigating the root cause and has confirmed that patient safety and existing global regulatory filings remain unaffected.
Semaglutide Product | 09/07/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy